GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 2021. Also, Altimmune’s Chief Medical Officer, Dr. Scott Harris, will be giving an oral presentation at the 2021 NASH-TAG Conference, being held March 11-13, 2021.
Details on the H.C. Wainwright fireside chat presentation are as follows:
|Title:||H.C. Wainwright Global Life Sciences Conference|
|Presenters:||Vipin Garg, Ph.D., Chief Executive Officer|
Scot Roberts, Ph.D., Chief Scientific Officer
Scott Harris, M.D., Chief Medical Officer
|Date/Time:||March 9, 2021 at 7:00 am ET|
A webcast link to the H.C. Wainwright fireside chat presentation will be accessible on the Events section of the Altimmune website.
Details on the NASH-TAG 2021 presentation by Dr. Scott Harris are as follows:
|Title:||Dual GLP-1 Agonists in the Treatment of Metabolic|
& Liver Dysfunction in NASH
|Presenter:||Scott Harris M.D., Chief Medical Officer |
|Date/Time:||March 13, 2021 at 9:30 pm ET|
A copy of the presentation materials will be accessible on the Events section of the Altimmune website.
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Investor & Media Contacts:
|Will Brown||Stacey Jurchison|
|Chief Financial Officer||Sr. Dir, Investor Relations|
|Phone: 240-654-1450||Phone : 410-474-8200|